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Therapeutic Drug Monitoring of Nevirapine
in Resource-Limited Settings
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Background. We developed a simple and inexpensive thin-layer chromatography (TLC) assay for semiquan-
titative detection of saliva concentrations of nevirapine in resource-limited settings. The method was validated in
an African target population.
Methods. Paired plasma and saliva nevirapine concentrations were assayed by high-performance liquid chro-
matography (HPLC); saliva concentrations of nevirapine were also assayed by TLC. The rate of false-positive
results was the proportion of subtherapeutic nevirapine saliva and plasma concentrations determined by HPLC
that were judged to be therapeutic in saliva specimens by TLC. The rate of false-negative results was the proportion
of therapeutic nevirapine saliva and plasma concentrations determined by HPLC that were judged to be sub-
therapeutic in saliva specimens by TLC. The extent of agreement in TLC readings between 5 technicians and 2
batches of TLC sheets was evaluated.
Results. Twenty-five (9%) of 286 African adults had a subtherapeutic plasma nevirapine concentration. The
median ratio of nevirapine concentrations in saliva to those in plasma was 0.51:1. The rate of false-positive results
for TLC was 0% (0 of 23 specimens) when TLC results were compared with HPLC results for saliva specimens
and 8% (2 of 25 specimens) when TLC results were compared with HPLC results for plasma specimens. The rate
of false-negative results for TLC was 1% (3 of 263 specimens) when TLC results were compared with HPLC results
for saliva specimens and 1% (3 of 261 specimens) when TLC results were compared with HPLC results for plasma
specimens. The extent of agreement of TLC results was substantial for the 5 technicians (Fleiss’s ) andkp 0.77
for the 2 batches of sheets (Cohen’s ).kp 0.80
Conclusions. The TLC assay was found to be sensitive, specific, and robust in the detection of subtherapeutic
nevirapine concentrations in saliva specimens obtained from African HIV-infected adults. It is an attractive alter-
native to HPLC for therapeutic drug monitoring of nevirapine in resource-limited settings.
Nevirapine is widely prescribed in combination with
nucleoside reverse-transcriptase inhibitors for the treat-
ment of HIV infection in resource-limited countries.
Adequate plasma concentrations of nevirapine are re-
quired to achieve a successful response, whereas sub-
therapeutic concentrations (defined as concentrations
!3.0 mg/L) are related to development of mutations
and virological failure [1–3]. Even in the case of perfect
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adherence to regimens at standard doses, some patients
will remain at risk for underdosing because of inter-
patient variability in nevirapine exposure or drug-drug
interactions.
In the developed world, therapeutic drug monitoring
(TDM) [3] is a well-known tool for the optimization
of nevirapine dosing in HIV-infected patients. As a re-
sult of a lack of simple and affordable methods to de-
termine the level of exposure to nevirapine, TDM is
hardly ever performed in resource-limited settings. Pre-
vious studies have suggested that saliva specimens may
be used as an alternative body fluid sample for TDM
of nevirapine [4, 5]. Saliva concentrations of nevirapine
in HIV-infected [4] and healthy [5] white persons are
approximately one-half of the values observed in
plasma specimens obtained from such persons. We re-
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method to provide a simple and economical tool for semi-
quantitative measurement of the saliva concentration of
nevirapine.
The primary objective of this study was to validate our newly
developed TLC method for TDM of nevirapine concentrations
in saliva samples obtained from HIV-infected Africans. Sec-
ondary objectives were to determine the relationship between
saliva and plasma nevirapine concentrations and the proportion
of subtherapeutic nevirapine concentrations in an African
population.
METHODS
Study population. Three hundred HIV-infected adults who
had been receiving a regimen that contained nevirapine for at
least 4 weeks were eligible for enrollment at a routine visit to
the adult HIV clinic of the Kilimanjaro Christian Medical Cen-
tre (Moshi, Tanzania). Patients who had oral lesions or ulcers
and those who were unable to self-report the date and time of
the most recent ingestion of nevirapine were excluded from the
study. The protocol was reviewed and approved by the Ethics
Committee of Tumaini University (Moshi). Written informed
consent was obtained from all subjects before enrollment.
Sample collection and drug concentration assays. At a
routine visit to the clinic, unannounced paired blood and saliva
samples were collected within 5 min of each other. Stimulated
saliva specimens were obtained with a salivette (Sartstedt; Etten-
Leur) using a dental cotton roll impregnated with citric acid
(20 mg), which stimulates the salivary flow. Study subjects were
asked to chew on the roll for ∼1 min. Blood and saliva samples
were stored at 2C–8C for a maximum of 8 h. Plasma was
separated and stored at 80C until transportation to The
Netherlands on dry ice. Saliva was obtained by centrifugation
of the cotton roll at 800 g for 10 min. Two aliquots were stored
at 80C: one for analysis by TLC in Tanzania, and one for
transportation to The Netherlands and analysis by high-per-
formance liquid chromatography (HPLC).
Saliva and plasma concentrations of nevirapine were deter-
mined at the Department of Clinical Pharmacy of the Radboud
University Nijmegen Medical Centre (Nijmegen, The Nether-
lands) using validated HPLC assays with UV detection, as mod-
ified from a method described by Hollanders et al. [6]. Samples
were pretreated as described by Hollanders and colleagues, and
preparation of saliva samples did not differ from preparation
of plasma samples. In brief, 150 mL of saliva or plasma was
mixed with 150 mL of perchloric acid, vortexed for 20 s, and
centrifuged for 5 min at 12,175 g. Subsequently, 200 mL of the
clear supernatant was transferred to insert vials and placed in
the autosampler. The lower and upper limits of quantification
of the modified assays were 0.167 and 16.7 mg/L, respectively,
for plasma and 0.158 and 15.8 mg/L, respectively, for saliva.
The intraday precision of the assays ranged from 0.4% to 3.2%
for plasma and from 1.3% to 4.1% for saliva. Additional var-
iation as a result of performing the assays on different days
ranged from 0.0% to 0.4% for plasma and from 0.8% to 2.2%
for saliva. The accuracy of the assays ranged from 102% to
105% for plasma and from 99% to 102% for saliva. Ratios of
saliva nevirapine concentration to plasma nevirapine concen-
tration and the proportion of subjects with a subtherapeutic
nevirapine plasma concentration (i.e., !3.0 mg/L) [3] were de-
termined. In addition, saliva concentrations of nevirapine were
semiquantitatively analyzed at the Biotechnology Laboratory of
Kilimanjaro Christian Medical Centre using a newly developed
TLC method.
Experimental TLC method. A reference solution of nevi-
rapine (Viramune; Boehringer Ingelheim), 1.75 mg/L, was ob-
tained by dilution of a stock solution (nevirapine, 0.875 mg/
mL, in dimethylsulfoxide [DMSO]; Merck) in blank saliva (i.e.,
saliva without nevirapine or any other drug). Both were kept
at 80C.
The reference solution and saliva samples were thawed at
room temperature, mixed for 1 min, and centrifuged at 9000
g for 1 min. Of the reference and samples, 1.0 mL was trans-
ferred into a 10-mL glass test tube. After addition of 0.5 mL
of 0.2 M ammonia (diluted from 25% ammonia; Labopharma)
and 5 mL tert-butylmethylether (Riedel–de Hae¨n), tubes were
closed, mixed for 1 min, centrifuged at 1150 g for 5 min, and
stored at 80C until the lower layer was frozen completely
(20 min). The organic layer was poured into a 10-mL glass test
tube and was dried in 2 days.
An eluent (or mobile phase) was prepared (ratio of toluene
to ethyl acetate, 1:1; ACME Chemicals and Unilab, respectively)
and poured into a TLC container. The container was closed
and left for 1 h. After addition of 50 mL of methanol to the
dried test tubes, they were closed and mixed for 1 min. One
mL of the reference and of the samples was slowly pipetted in
small, dense dots at least 1.5 cm from the side and 2.0 cm from
the bottom of a silica gel TLC sheet (height, 10.0 cm; width,
20.0 cm; Merck), as shown in figure 1. After drying, spots were
checked for similarity of size and shape under UV light (254
nm; CAMAG 022.9120). The TLC sheet was placed in the
container with eluent for ∼12 min (figure 2). It was marked
for the distance that the eluent had moved and was dried in
the air. The intensity of the spots was determined under UV
light and compared with the reference spot (figure 3). A spot
that was less intense than the reference was considered to be
subtherapeutic. A spot that was comparable to or more intense
than the reference spot was considered to be therapeutic.
Technical validation of TLC method. All saliva samples
were used to determine the technical sensitivity and specificity
of the TLC method. The readings were performed by 1 tech-
nician. Saliva nevirapine concentrations determined by HPLC
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Figure 1. Preparation of thin-layer chromatography sheet with saliva
samples.
Figure 2. Thin-layer chromatography sheet in container with eluent
is one-half of the cutoff value for plasma specimens (3.0 mg/
L) [3]. The rate of false-positive results was defined as the
proportion of subtherapeutic saliva concentrations of nevira-
pine (i.e., !1.5 mg/L), as determined by HPLC [6], that were
reported to be therapeutic on the basis of TLC of saliva spec-
imens. The rate of false-negative results was defined as the
proportion of therapeutic saliva concentrations of nevirapine
(1.5 mg/L), as determined by HPLC [6], that were reported
to be subtherapeutic on the basis of TLC of saliva specimens.
Twenty-five saliva samples with nevirapine concentrations
determined by HPLC [6] closest to the TLC reference value of
1.75 mg/L were selected to test the robustness of the TLC
method. The extent of agreement in TLC result between 5
different technicians (Fleiss’s k [7]) and 2 different batches of
TLC sheets (Cohen’s k [8]) was evaluated in these 25 saliva
samples.
The stability of the stock solution (nevirapine in DMSO)
was tested after storage at 40C for 50 months. The stability
of the reference solution (nevirapine in blank saliva) was tested
after storage at room temperature for 17 h, after storage at
40C for 2 months, and after freezing and thawing twice.
Interference of possible concurrently used medications was
evaluated by comparison of the retention factor (i.e., the dis-
tance travelled by compound divided by distance travelled by
eluent front) of extractable and detectable (UV light; 254 nm)
compounds with the retention factor value of nevirapine. In
addition, blank saliva samples obtained from at least 6 subjects
who had not been taking nevirapine were tested for interference
by endogenous substances.
Biological validation of TLC method. All plasma and saliva
samples were used to determine the biological sensitivity and
specificity of the TLC method. The rate of false-positive results
was defined as the proportion of subtherapeutic nevirapine
plasma concentrations (!3.0 mg/L [3]) determined by HPLC
[6] that were reported to be therapeutic on the basis of TLC
of saliva specimens. The rate of false-negative results was de-
fined as the proportion of therapeutic nevirapine plasma con-
centrations (3.0 mg/L [3]) determined by HPLC [6] that were
reported to be subtherapeutic on the basis of TLC of saliva
specimens.
RESULTS
Of the 300 subjects enrolled in the study, 14 were excluded
because of problems with labelling, because the saliva volume
was too small, or because the saliva specimen was lost. The
mean age of the remaining 286 African subjects (200 of whom
were women) was 41 years (range, 17–71 years). All subjects
were treated with a nevirapine dosage of 200 mg twice per day,
in combination with lamivudine and either stavudine or
zidovudine.
The mean plasma concentration of nevirapine, as determined
by HPLC, was 7.35 mg/L (range, !0.167 to 28.59 mg/L).
Twenty-five (9%) of 286 subjects had a subtherapeutic plasma
nevirapine concentration (i.e., !3.0 mg/L); 18 of 25 had a con-
centration that was less than the detection limit of the HPLC
assay (i.e., !0.15 mg/L). The median ratio of saliva nevirapine
concentration to plasma nevirapine concentration, as deter-
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Figure 3. Determination of spot intensity under UV light
:1), and the median time from the last ingestion of medication
and to sample collection was 3.40 h (interquartile range, 2.52–
4.37 h). Six subjects had a ratio of saliva nevirapine concen-
tration to plasma nevirapine concentration 11.00 (range, 1.25–
15.68); the median time from last ingestion of medication to
sampling for these 6 subjects was 1.19 h (interquartile range,
0.85–1.74 h).
None of the 23 saliva specimens that were found to contain
subtherapeutic concentrations of nevirapine (i.e., !1.5 mg/L)
by HPLC were reported to have therapeutic values by TLC
(rate of false-positive results, 0%); the technical sensitivity of
the TLC method was 100% (table 1). Three of the 263 saliva
specimens that were found to have therapeutic concentrations
of nevirapine (i.e., 1.5 mg/L; 1.62, 1.74, and 1.96 mg/L) by
HPLC were reported to have subtherapeutic values by TLC
(rate of false-negative results, 1%); the technical specificity of
the TLC method was 99% (table 1).
The extent of agreement among TLC results (i.e., subther-
apeutic or therapeutic nevirapine saliva concentrations) for 25
selected samples with a concentration closest to the reference
sample was substantial for the 5 technicians (Fleiss’s k, 0.77)
and 2 batches of TLC sheets (Cohen’s k, 0.80).
The stock solution for the TLC method (nevirapine in
DMSO) was stable at 40C for at least 50 months (mean rate
of , 99.7%0.3%). The reference solution (ne-recovery SD
virapine in blank saliva) was stable at room temperature for at
least 17 h (mean rate of , 107.6%5.8%) andrecovery SD
at 40C for at least 2 months (mean rate of ,recovery SD
94.3%3.2%). Freezing and thawing twice had no effect on
the stability of nevirapine in blank saliva (mean rate of
, 95.1%1.1%). The mean nevirapine reten-recovery SD
tion factor value was 0.29; none of the possible comedications
that were extractable and detectable had a similar retention
factor value. Also, no interference by endogenous substances
was observed in the blank saliva samples obtained from subjects
not taking nevirapine.
Two of the 25 plasma samples found to have subtherapeutic
nevirapine concentrations (!3.0 mg/L; 2.61 and 2.91 mg/L) by
HPLC were reported to have therapeutic concentrations by TLC
(rate of false-positive results, 8%); the biological sensitivity of
the TLC method was 92% (table 1). Three of the 261 plasma
samples found to have therapeutic nevirapine concentrations
(3.0 mg/L; 3.41, 3.52, and 4.28 mg/L) by HPLC were reported
to have subtherapeutic concentrations by TLC (rate of false-
negative results, 1%); the biological specificity of the TLC
method was 99% (table 1).
DISCUSSION
Twenty-five (9%) of 286 HIV-infected African adults had a
subtherapeutic plasma concentration of nevirapine (i.e., !3.0
mg/L) [3]. Saliva nevirapine concentrations were approximately
one-half of the values observed in plasma specimens. A TLC
method for semiquantitative detection of nevirapine in saliva
specimens was found to be sensitive, specific, and robust. This
simple and economical tool is a good option for TDM of ne-
virapine in resource-limited settings.
Use of saliva specimens instead of plasma specimens for
TDM of nevirapine implies painless and noninvasive sampling,
a diminished risk of HIV transmission to health care workers,
and a lower cost [4]. TLC is a relatively inexpensive assay
technique, compared with HPLC [9], which is commonly used
in the developed world for TDM of nevirapine in plasma sam-
ples. An HPLC system for TDM of nevirapine costs approxi-
mately i40,000, and the costs for consumables per sample are
estimated to be i15. In contrast, the estimated initial setup cost
of a new TLC method for semiquantitative measurement of
nevirapine in saliva is i800, and the cost of consumables per
sample is approximately i1.60. Because this simple and inex-
pensive method was developed to perform TDM of nevirapine
in resource-limited settings, it was validated in an African target
population in our study.
The percentage of HIV-infected adults in our Tanzanian pop-
ulation (9%) with a subtherapeutic plasma concentration of
nevirapine [3], as determined by HPLC [6], was lower than
the percentage in a previous report from Malawi (16%) [10].
This may be associated with the unreliable drug supply during
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Table 1. Number of patients with (sub)therapeutic nevirapine concentrations according to thin-layer
chromatography (TLC), compared with according to high-performance liquid chromatography (HPLC), and
sensitivity and specificity of the TLC assay.
Specimen, concentration determined by HPLC











Subtherapeutic concentration 23 0 100 …
Therapeutic concentration 3 260 … 99
Plasma
Subtherapeutic concentration 23 2 92 …
Therapeutic concentration 3 258 … 99
NOTE. Subtherapeutic concentrations of nevirapine were defined as !1.75 mg/L for TLC of saliva specimens, !1.5 mg/L
for HPLC of saliva specimens, and !3.0 mg/L for HPLC of plasma specimens. Therapeutic concentrations were defined as
values greater than these cutoff values.
than one-third of the total reported nonadherence to treatment
[10]. The fact that 18 of the 25 subtherapeutic nevirapine
plasma concentrations in our Tanzanian population were un-
detectable indicates nonadherence to treatment, because ne-
virapine is generally detected up to weeks after termination of
drug intake because of its long elimination half-life [11].
The median ratio of saliva nevirapine concentration to
plasma nevirapine concentration of 0.51:1, as determined by
HPLC [6], in our population of HIV-infected Africans was
comparable to the ratios observed in HIV-infected [4] and
healthy [5] white persons. It has been suggested that thorough
rinsing of the mouth is required before saliva sampling, because
remnants of orally administered medicines may contaminate
saliva specimens and yield spuriously high values [12]. Indeed,
6 of 286 subjects in our study had an unexpectedly high ratio
of saliva to plasma nevirapine concentration of 11:1 [4, 12];
this may be because the subjects had chewed tablets without
rinsing the mouth before samples were obtained. This expla-
nation is supported by our observation that the time between
last ingestion and sampling was shorter for subjects with un-
expectedly high nevirapine concentrations in saliva specimens,
compared with concentrations in plasma specimens.
Because the saliva nevirapine concentrations determined by
HPLC were approximately one-half of the values observed in
plasma specimens, they were defined as subtherapeutic if they
were !1.5 mg/L rather than if they were less than the cutoff
value for plasma (i.e., 3.0 mg/L) [3]. The main requirement of
our TLC method for semiquantitative detection of nevirapine
in saliva specimens was appropriate sensitivity, meaning de-
tection of nevirapine concentrations that were found to be
subtherapeutic by HPLC, to pick out subjects at risk for ne-
virapine resistance. During the development of our TLC
method, subtherapeutic saliva concentrations slightly less than
1.5 mg/L were sufficiently distinguishable from a TLC reference
value of 1.75 mg/L but not from a reference value of 1.5 mg/
L. Therefore, for the validation of our TLC method, we chose
a reference value of 1.75 mg/L, which led to excellent technical
sensitivity (100%) and specificity (99%). None of the subther-
apeutic nevirapine saliva concentrations found by HPLC were
reported to be therapeutic by TLC, and the few therapeutic
saliva concentrations that were reported to be subtherapeutic
by TLC were all close to the cutoff value for saliva (1.5 mg/L).
Biological validation compared saliva concentrations of ne-
virapine determined by TLC with plasma concentrations de-
termined by HPLC (either subtherapeutic or therapeutic levels),
finding acceptable sensitivity (92%) and excellent specificity
(99%). False-positive and false-negative results were all close
to the cutoff value for plasma (3.0 mg/L). The somewhat lower
biological sensitivity can be explained by the fact that some
subjects with a subtherapeutic plasma concentration deter-
mined by HPLC had a therapeutic saliva concentration ac-
cording to both HPLC and TLC. Although these subjects had
a higher ratio of saliva to plasma nevirapine concentration than
average, none of them had a ratio 11:1.
As expected, it was found to be most difficult to interpret
nevirapine saliva concentrations that were closest to the TLC
reference value. To test the worst-case scenario robustness of
the TLC method, we selected 25 samples closest to the reference
value. The fact that the extent of agreement in TLC results
between 5 technicians and 2 batches of TLC sheets was sub-
stantial provides an indication that the outcome of our TLC
method is reliable during normal use.
We are planning to roll out the TLC method in various
African countries and in Indonesia. This will make it possible
to continue to evaluate the method’s robustness and its practical
application to adherence monitoring. Potentially, the assay
could be further developed commercially.
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method for semiquantitative determination of saliva concen-
trations of nevirapine. The assay was found to be sensitive,
specific, and robust for detection of subtherapeutic nevirapine
concentrations in an African population. It is an attractive al-
ternative to HPLC for TDM of nevirapine in resource-limited
settings.
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